Phase I trial of volasertib, a Polo-like kinase inhibitor, in Japanese patients with acute myeloid leukemia

Cancer Science

Volumn 106, Issue 11, 2015, Pages 1590-1595

  Kobayashi, Yukio ^a   Yamauchi, Takahiro ^b   Kiyoi, Hitoshi ^c   Sakura, Toru ^d   Hata, Tomoko ^e   Ando, Kiyoshi ^f   Watabe, Aiko ^g   Harada, Akiko ^g   Taube, Tillmann ^h   Miyazaki, Yasushi ^e   Naoe, Tomoki ⁱ  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b UNIVERSITY OF FUKUI   (Japan)

^c NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d SAISEIKAI MAEBASHI HOSPITAL   (Japan)

^e NAGASAKI UNIVERSITY HOSPITAL   (Japan)

^f TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g NIPPON BOEHRINGER INGELHEIM CO LTD   (Japan)

^h BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

ⁱ NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

Author keywords

Acute myeloid leukemia; Clinical trial phase I; Japanese; Maximum tolerated dose; Polo like kinase 1

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; GRANULOCYTE COLONY STIMULATING FACTOR; VOLASERTIB; ANTINEOPLASTIC AGENT; CELL CYCLE PROTEIN; ONCOPROTEIN; POLO-LIKE KINASE 1; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; PTERIDINE DERIVATIVE;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL PROTOCOL; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DECREASED APPETITE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG ELIMINATION; DRUG SAFETY; DRUG TISSUE LEVEL; DRUG WITHDRAWAL; ELECTROCORTICOGRAPHY; ELIMINATION HALF-LIFE; EPISTAXIS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HUMAN; HYPERURICEMIA; HYPOALBUMINEMIA; HYPOKALEMIA; INFECTION; JAPANESE (PEOPLE); KARYOTYPE; LIVER FUNCTION TEST; LIVER INJURY; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; RETREATMENT; SEPSIS; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VERY ELDERLY; VOLUME OF DISTRIBUTION; VOMITING; ANTAGONISTS AND INHIBITORS; ASIAN CONTINENTAL ANCESTRY GROUP; CLINICAL TRIAL; DOSE RESPONSE; JAPAN; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; CELL CYCLE PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; JAPAN; LEUKEMIA, MYELOID, ACUTE; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PTERIDINES;

EID: 84983094912     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12814     Document Type: Article

References (20)

1. National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology. Acute Myeloid Leukemia. Version 1.2015. [Cited 10 August 2015.] Available from URL: http://www.nccn.org.
2. Kantarjian H, O'Brien S. Questions regarding frontline therapy of acute myeloid leukemia. Cancer 2010; 116: 4896-901.
3. DiNardo CD, Cortes JE. New treatment for acute myelogenous leukemia. Expert Opin Pharmacother 2015; 16: 95-106.
4. Craddock C, Tauro S, Moss P, Grimwade D. Biology and management of relapsed acute myeloid leukaemia. Br J Haematol 2005; 129: 18-34.
5. Schöffski P. Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology. Oncologist 2009; 14: 559-70.
6. Strebhardt K. Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy. Nat Rev Drug Discov 2010; 9: 643-60.
7. Renner AG, Dos Santos C, Recher C et al. Polo-like kinase 1 is overexpressed in acute myeloid leukemia and its inhibition preferentially targets the proliferation of leukemic cells. Blood 2009; 114: 659-62.
8. Takai N, Hamanaka R, Yoshimatsu J, Miyakawa I. Polo-like kinases (Plks) and cancer. Oncogene 2005; 24: 287-91.
9. Chopra P, Sethi G, Dastidar SG, Ray A. Polo-like kinase inhibitors: an emerging opportunity for cancer therapeutics. Expert Opin Investig Drugs 2010; 19: 27-43.
10. Smith MR, Wilson ML, Hamanaka R et al. Malignant transformation of mammalian cells initiated by constitutive expression of the polo-like kinase. Biochem Biophys Res Commun 1997; 234: 397-405.
11. Rudolph D, Steegmaier M, Hoffmann M et al. BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity. Clin Cancer Res 2009; 15: 3094-102.
12. Rudolph D, Impagnatiello MA, Blaukopf C et al. Efficacy and mechanism of action of volasertib, a potent and selective inhibitor of Polo-like kinases, in preclinical models of acute myeloid leukemia. J Pharmacol Exp Ther 2015; 352: 579-89.
13. Döhner H, Bug G, Müller-Tidow C et al. Phase I/II study of volasertib, an intravenous Polo-like kinase inhibitor (Plk), in patients with relapsed/refractory acute myeloid leukemia (AML): updated phase I results for volasertib monotherapy. Haematologica 2014; 99: S649.
14. Cheson BD, Bennett JM, Kopecky KJ et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003; 21: 4642-9.
15. Döhner H, Estey EH, Amadori S et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010; 115: 453-74.
16. Döhner H, Lübbert M, Fiedler W et al. Randomized, phase 2 trial comparing low-dose cytarabine with or without volasertib in AML patients not suitable for intensive induction therapy. Blood 2014; 124: 1426-33.
17. Force T, Kolaja KL. Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes. Nat Rev Drug Discov 2011; 10: 111-26.
18. Kloth JSL, Pagani A, Verboom MC et al. Tyrosine kinase inhibitors and QTc intervals: a class effect. ASCO Meeting Abstracts 2014; 32: 2590.
19. Schöffski P, Awada A, Dumez H et al. A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours. Eur J Cancer 2012; 48: 179-86.
20. Lin C-C, Su W, Yen C-J et al. A phase I study of two dosing schedules of volasertib (BI 6727), an intravenous Polo-like kinase inhibitor, in patients with advanced solid malignancies. Br J Cancer 2014; 110: 2434-40.